Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research news
Smartphone cognitive testing for frontotemporal lobar degeneration
Findings from a new study suggest that smartphones could offer a feasible, reliable, valid, and scalable solution for remote evaluations of frontotemporal lobar degeneration, a neurodegenerative pathology causing early-onset dementia syndromes, and may improve early detection.
One-third of patients with TBI have marginal or inadequate health literacy
Low health literacy is a problem for a substantial proportion of people with moderate to severe traumatic brain injury (TBI), according to research published in The Journal of Head Trauma Rehabilitation (JHTR). The official journal of the Brain Injury Association of America, JHTR is published in the Lippincott portfolio by Wolters Kluwer.
Mechanism found to determine which memories last
Neuroscientists have established in recent decades the idea that some of each day’s experiences are converted by the brain into permanent memories during sleep the same night. A new study led by researchers from NYU Grossman School of Medicine has now proposed a mechanism that determines which memories are tagged as important enough to linger in the brain until sleep makes them permanent.
Company and financial neuro-rehab news
Evolving Landscape in Alzheimer’s Disease
Cognition Therapeutics will host a virtual KOL event on Friday, April 12, 2024 from 8:00 AM to 9:30 AM ET. The event will feature three experts who will provide insights on the unmet need and the current treatment landscape for Alzheimer’s disease, as well as anti-amyloid beta monoclonal antibody drug launches, and commercial uptake. The KOLs and Cognition management will discuss CT1812, Cognition’s novel oral once-daily sigma-2 (σ-2) receptor modulator designed to displace Aβ oligomers from their binding sites on neurons. Topics will include details of its mechanism of action and ongoing clinical development program in Alzheimer’s disease, which includes the Phase 2 START Study in people with early stage disease and the Phase 2 SHINE Study in people with mild-to-moderate Alzheimer’s disease.
CervoMed announces up to $149.4m private placement
Clinical-stage company focused on developing treatments for age-related neurologic disorders, CervoMed, has announced that it has entered into a definitive securities purchase agreement for a private placement. It anticipates the possible gross proceeds from the private placement to be approximately $50 million, which will be used to fund research and development of its clinical-stage product candidate, neflamapimod, working capital and general corporate purposes.
Policy, legislation and society news
Should we be worried about Neurotechnology?
The Strategist explores the impact of emerging technologies on society. “What we do know is that AI and other rapidly advancing technologies, such as quantum computing, biotechnology, neurotechnology, and climate-intervention tech, are growing increasingly powerful and influential by the day. Despite the scandals and the political and regulatory backlash of the past few years, Big Tech firms are still among the world’s largest companies and continue to shape our lives in myriad ways, for better or worse.”
